期刊文献+

安立生坦关键中间体的合成新方法 被引量:1

A Novel Synthetic Route for the Key Intermediate of Ambrisentan
原文传递
导出
摘要 安立生坦(1)是一种内皮素-1受体拮抗药,2-羟基-3-甲氧基-3,3-二苯基丙酸(2)是合成1的关键中间体,本研究报道了合成2的新方法。二苯甲酮(3)与磷酰基乙酸三乙酯经Wittig-Horner反应生成3,3-二苯基丙烯酸乙酯(4)。以甲醇为溶剂,4与N-溴代丁二酰亚胺(NBS)亲电加成得到2-溴-3-甲氧基-3,3-二苯基丙酸乙酯(5)。5与乙酸酯化生成2-乙酰氧基-3-甲氧基-3,3-二苯基丙酸乙酯(6),无需分离纯化直接水解得到2,总收率75%。该工艺原料价廉易得、操作简便,避开了Darzens缩合反应,适合工业化生产。 Ambrisentan(1)is an endothelin-1 receptor antagonist.In this paper,a novel synthetic route for 2-hydroxy-3-methoxy-3,3-diphenylpropanoic acid(2),the key intermediate of 1,was reported.Ethyl 3,3-diphenylacrylate(4)was obtained from benzophenone(3)with triethyl phosphatoacetate by Wittig-Horner reaction.Ethyl 2-bromo-3-methoxy-3,3-diphenylpropanoate(5)was synthesized by electrophilic addition of 4 with NBS in methanol.Compound 5 was esterified with acetic acid to give ethyl 2-acetoxy-3-methoxy-3,3-diphenylpropanoate(6),and then without separation,6 was hydrolyzed directly to obtain 2 in a total yield of 75%.In this process,the materials are cheap and easily available,and it avoids the Darzens condensation reaction,which is suitable for industrial production.
作者 贾姝 张聪聪 王硕 姚晓敏 JIA Shu;ZHANG Congcong;WANG Shuo;YAO Xiaomin(School of pharmacy,Zhejiang Pharmaceutical College,Ningbo 315100)
出处 《中国医药工业杂志》 CAS CSCD 北大核心 2021年第2期207-210,共4页 Chinese Journal of Pharmaceuticals
基金 2015年度省公益技术应用研究计划项目(2015C33202) 宁波市科技惠民计划项目(2015C50020) 2017年浙江省大学生科技创新项目(2017R435005)给予支持
关键词 安立生坦 关键中间体 2-羟基-3-甲氧基-3 3-二苯基丙酸 合成新方法 ambrisentan key intermediate 2-hydroxy-3-methoxy-3,3-diphenylpropanoic acid novel synthetic route
  • 相关文献

参考文献7

二级参考文献58

  • 1郭文.肺动脉高压治疗的潜力药物即将崛起[J].上海医药,2007,28(4):160-161. 被引量:2
  • 2Hrometz SL, Shields KM. Role of ambrisentan in the management of pulmonary hypertension [J]. Ann Pharmacother, 2008, 42 (11) : 1653-1659.
  • 3Cheng JW. Ambrisentan for the management of pulmonary arterial hypertension [J]. Clin Ther, 2008, 30 (5) : 825-833.
  • 4Riechers H, Albrecht HE Amberg W, et al. Discovery and optimization of a novel class of orally active nonpeptidic endothelin-A receptor antagonists [J]. J Med Chem, 1996, 39 (11) : 2123-2128.
  • 5Riechers H, Klinge D, Amberg W, et al. New carboxylic acid derivatives, their preparation and their use: EP, 0785926 [P]. 2001-08-22.
  • 6Jansen R, Knopp M, Amberg W, et al. Structural similarity and its surprises: endothelin receptor antagonists--Process research and development report [J]. Org Proc Res Dev, 2001, 5(1): 16-22.
  • 7mberg W, Hergenrder S, Hillen H, et al. Discovery and synthesis of (S) -3- [2- (3,4-dimethoxyphenyl) ethoxy] -2- (4,6-dimethylpyrimidin-2-yloxy)-3,3- diphenylpropionic acid (LU302872), a novel orally active mixed ET/ET receptor antagonist [J]. J Med Chem, 1999, 42 (16) : 3026-3032.
  • 8Bessard Y, Crettaz R. Rate acceleration of nucleophilic substitution of 2-chloro-4,6-dimethoxypyrimidine by sulfinate catalysis [J]. Tetrahedron, 2000, 56 (27) : 4739-4745.
  • 9Riechers H,Albrecht H P,Amberg W,etal.J Med Chem[J],1996,39(11).2123-2128.
  • 10Jansen R,Knopp M,Bernard H,et al.Org Pro Res Dev[J],2001,5(1),16-22.

共引文献19

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部